Mesothelioma Marker Antibody (HBME-1): sc-59307
- Mesothelioma Marker Antibody (HBME-1) is a mouse monoclonal IgM Mesothelioma Marker antibody, cited in 1 publications, provided at 100 µl
- raised against a suspension of mesothelioma cells of human origin
- recommended for detection of an antigen on microvilli of mesothelioma cells of human origin by IF and IHC(P)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Mesothelioma Marker Antibody (HBME-1). This work is in progress.
QUICK LINKS
SEE ALSO...
Mesothelioma Marker Antibody (HBME-1) is a mouse monoclonal IgM antibody that detects the Mesothelioma Marker protein of human origin by immunofluorescence (IF) and immunohistochemistry with paraffin-embedded sections (IHCP). Anti-Mesothelioma Marker antibody (HBME-1) is available as a non-conjugated form, playing a crucial role in the diagnosis and study of mesothelioma, a highly aggressive cancer primarily linked to asbestos exposure. Mesothelioma Marker (HBME-1) antibody helps identify malignant mesothelial cells, which proliferate within the mesothelium, the protective lining of internal organs. Understanding Mesothelioma Marker protein structure is vital, as a series of immunoglobulin-like domains facilitate cell adhesion and signaling. These structural features enable Mesothelioma Marker protein to interact with other cellular components, influencing tumor behavior and progression. Anti-Mesothelioma Marker antibody (HBME-1) detection and characterization can provide valuable insights into the tumor microenvironment and aid in developing targeted therapies, ultimately improving patient outcomes in a disease that often presents with late-stage symptoms and limited treatment options.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Mesothelioma Marker Antibody (HBME-1) References:
- Mesothelioma research as a social issue. | Hahn, CE. 2006. Inhal Toxicol. 18: 991-4. PMID: 16920673
- Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma. | Hiraki, A., et al. 2006. Cancer Sci. 97: 1175-81. PMID: 16939492
- Cytogenetic and molecular genetic changes in malignant mesothelioma. | Musti, M., et al. 2006. Cancer Genet Cytogenet. 170: 9-15. PMID: 16965949
- [Malignant mesothelioma--diagnosis and treatment strategies]. | Nakano, T. 2006. Gan To Kagaku Ryoho. 33: 1215-20. PMID: 16969013
- Portal site metastasis of invasive mesothelioma after diagnostic thoracoscopy in a dog. | Brisson, BA., et al. 2006. J Am Vet Med Assoc. 229: 980-3. PMID: 16978119
- Malignant mesothelioma of the pleura among seafarers. | Bianchi, C., et al. 2005. Med Lav. 96: 490-5. PMID: 16983974
- The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo. | Yoneda, T., et al. 2006. DNA Cell Biol. 25: 530-40. PMID: 16989576
- Biology and management of malignant pleural mesothelioma. | Zucali, PA. and Giaccone, G. 2006. Eur J Cancer. 42: 2706-14. PMID: 16989994
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mesothelioma Marker Antibody (HBME-1) | sc-59307 | 100 µl | $322.00 |